Browse the evidence

Patients with severe obesity carrying a high genetic risk score for waist-hip ratio (WHR GRS) experience significantly reduced weight loss from a 24-week milk-based meal replacement program compared to those with lower WHR GRS.

If you have a family history of carrying weight around your waist, standard meal replacement diets might be less effective for you than for others. This doesn't mean you can't lose weight, but you may need to manage expectations regarding the speed and magnitude of loss, or consider more intensive support. Genetic testing for waist-hip ratio risk could help tailor your approach.

Higher consumption of ultraprocessed foods (UPFs) is positively associated with the prevalence of overall arthritis and specifically rheumatoid arthritis (RA) in U.S. adults, but not osteoarthritis (OA).

If you have arthritis or are at risk, reducing your intake of ultraprocessed foods (like sugary drinks, packaged snacks, and fast food) may help lower your risk of developing rheumatoid arthritis. This is because UPFs often drive inflammation and weight gain. You don't need to eliminate them entirely, but shifting your diet towards less processed options can have a measurable benefit.

A 5-week nutritional intervention combining a 3-week very low-calorie ketogenic diet (VLCKD) and a 2-week low-carbohydrate ketogenic diet (LCKD) significantly improves metabolic comorbidities—including BMI, blood pressure, lipid profiles, and insulin sensitivity—in patients with Cushing's disease.

If you have Cushing's disease, a structured 5-week ketogenic diet (starting with very low calories and carbs, then slightly increasing calories while keeping carbs low) can significantly improve your weight, blood pressure, and cholesterol. Importantly, this diet did not raise your cortisol levels, which is a common fear. This should be done alongside your prescribed medication and with a multivitamin supplement to ensure nutrient adequacy.

Integrative Korean Medicine Treatment (IKMT), comprising personalized herbal medicine (including Ephedrae Herba) and dietitian-led lifestyle modification, produces statistically significant weight loss and blood pressure reductions in obese adults with a safety profile comparable to or better than GLP-1 receptor agonists.

This study suggests that a structured program combining personalized herbal medicine (specifically containing Ephedrae Herba) with professional dietary coaching can lead to significant weight loss (average ~8.7%, up to ~28% in best responders) and improved blood pressure. It serves as a viable alternative for individuals who cannot tolerate or afford GLP-1 medications, provided they undergo proper medical screening for contraindications like heart or liver disease.

GLP-1 receptor agonists used for weight management are associated with nutritional deficiencies, specifically protein deficiency and metabolic acidosis, which may lead to malnutrition.

When using GLP-1 medications for weight loss, pay attention to your nutrition. Reports suggest a higher risk of protein deficiency and metabolic acidosis. Ensure you are eating enough protein and staying hydrated. If you feel unwell, dizzy, or experience unusual symptoms, talk to your doctor about your diet and medication.

Higher adherence to sports nutrition guidelines, measured by the Athlete Diet Index (ADI), is associated with lower fat mass in professional athletes.

For professional athletes, eating according to sports nutrition guidelines (high ADI score) is linked to having the lowest body fat. For non-professionals, this link is weaker. If you are serious about body composition, aligning your diet with established sports nutrition standards is a key lever, especially if you have access to professional guidance.

Short-duration napping (25-45 minutes) significantly improves mean power output in elite male kickboxers compared to no napping, without affecting countermovement jump height.

Elite kickboxers should consider incorporating 25-45 minute strategic naps before high-intensity training or competition. Ensure the environment is dark and quiet, and avoid screens during the nap. This intervention significantly boosts mean power output without negatively impacting explosive jump height.

Pre-race caffeine intake of 3-6 mg/kg or intra-race intake of 1-2 mg/kg may improve performance in ultra-marathons.

Consider using caffeine to boost performance. Take 3-6 mg/kg before the race and 1-2 mg/kg during the race. Test this during training to avoid GI issues. Caffeine can help with concentration and muscle function in long races.

Regular physical activity reduces the risk of breast, colon, and prostate cancers and improves survival rates for these patients.

If you have breast, colon, or prostate cancer, regular physical activity can help reduce your risk of recurrence and improve your survival rates. It is safe during and after treatment and can help manage fatigue and improve your quality of life. Consult your oncology team for a personalized exercise plan.

Dietary interventions that modulate gut microbiota composition (specifically increasing SCFA-producing bacteria and reducing dysbiosis) improve metabolic health outcomes including insulin sensitivity and glucose tolerance.

To improve your metabolic health, focus on dietary patterns that support a diverse gut microbiome. This means consuming a variety of plant fibers (prebiotics) to encourage the growth of beneficial bacteria that produce short-chain fatty acids (SCFAs). These SCFAs help regulate blood sugar and insulin sensitivity. Avoid highly processed foods that can cause dysbiosis (microbial imbalance) and inflammation.

High-fat diets induce gut barrier defects and metabolic endotoxemia (elevated LPS), which triggers low-grade inflammation and compromises insulin sensitivity.

Reducing chronic high-fat intake can help maintain gut barrier integrity, preventing the leakage of inflammatory bacterial components (LPS) into the bloodstream, which may improve insulin sensitivity.

Autoregulated single repetition sets at RPE 9-9.5 may minimize training time but are less likely to produce meaningful strength gains compared to the standard METD protocol.

If you are extremely time-crunched, you can try doing just one heavy single at RPE 9-9.5 per session. However, be aware that this method is less effective for building strength. To get better results with minimal extra time, add 2-3 'back-off' sets at 80% of your single's weight.

High-volume static stretching (≥15 minutes per muscle group, >3 times per week) induces muscle hypertrophy and strength increases comparable to resistance training, primarily by generating high-magnitude mechanical tension that activates mTOR/p70S6K signaling pathways.

If you cannot lift weights due to injury, age, or lack of equipment, perform static stretches for at least 15 minutes per muscle group, 3 or more times a week. Push to the point of discomfort (but not sharp pain). This can build muscle and strength similarly to weightlifting, though it takes longer per session. It is particularly useful for immobilized patients or as a supplement to your regular workouts.

Inter-set palm or sole cooling (10-15°C for 1-3 minutes) may acutely enhance resistance training volume capacity and maximal strength, though evidence is mixed and methodologically limited.

If you want to try inter-set cooling, use 10-15°C cooling on your palms (for upper body) or soles (for lower body) for 1-3 minutes between sets. You can use cold water buckets or ice packs. Be aware that results are inconsistent; some people may see increased volume or strength, while others see no change. It is not a guaranteed performance enhancer, but it is low-risk and may help some individuals tolerate more volume.

Training with 4-6 or 1-3 repetitions in reserve (RIR) yields comparable strength gains, whereas training to momentary failure (0 RIR) or near-failure (0-3 RIR) results in slightly inferior strength outcomes in trained men.

For strength gains, you do not need to train to failure. Stopping sets with 1-3 reps left in the tank (RIR) produces similar or better strength results than going to failure. Training to failure may actually hinder strength progress due to excessive fatigue and reduced recovery capacity. Focus on maintaining bar speed and consistency rather than absolute exhaustion.

Training sets to submaximal proximities of failure (4-6 RPE or 7-9 RPE) yields strength gains comparable to training with higher proximities, while training to momentary failure (10 RPE) may result in slightly inferior strength outcomes.

You do not need to train to failure to get strong. Training sets to 4-6 or 7-9 RPE (leaving 4-9 reps in reserve) produces strength gains similar to each other. Training to absolute failure (10 RPE) may actually hinder strength progress due to excessive fatigue. Focus on maintaining barbell velocity and managing recovery rather than grinding out every last rep.

Higher pre-diet daily gut microbiota plasticity predicts greater 12-month sustained weight loss specifically in individuals following a low-fat diet, but not a low-carb diet.

If you are following a low-fat diet, your gut microbiome's ability to change day-to-day (plasticity) before you start may predict your success. Men with higher pre-diet plasticity lost more weight and adhered better. Women did not show this correlation. For low-carb diets, pre-diet plasticity was not a predictor of success, though plasticity *during* the first 10 weeks was higher in successful users. Do not rely on static microbiome tests to predict success; focus on adherence.

Gut microbiota plasticity during the first 10 weeks of a dietary intervention correlates with weight loss success in a diet-dependent manner, with significant findings for low-carb dieters but not low-fat dieters.

If you are on a low-carb diet, the amount your gut microbiome changes in the first 10 weeks may predict your long-term success. Those who lost the most weight showed greater shifts in their microbiota during this period. This predictor does not apply to low-fat dieters, for whom pre-diet plasticity is the key factor.

Higher body mass index (BMI) is associated with lower self-reported physical functioning and overall health-related quality of life (HRQoL) in people with overweight or obesity.

If you have overweight or obesity, you are statistically more likely to experience reduced physical functioning and lower quality of life as your BMI increases. This is not just about appearance; it affects your daily physical capacity and general health perception. Addressing weight and associated comorbidities is a key lever for improving these functional outcomes.

The presence of cardiovascular (CV) or metabolic comorbidities significantly reduces health-related quality of life (HRQoL) and work productivity in people with overweight or obesity, independent of BMI alone.

Having overweight or obesity is not the only factor affecting your health and work. If you have cardiovascular or metabolic conditions (like diabetes or high blood pressure), these significantly impact your quality of life and productivity. Treating these comorbidities alongside weight management is crucial for improving your daily well-being.

People with overweight or obesity experience significant work productivity impairment, particularly in terms of presenteeism and activity impairment, when they have metabolic comorbidities.

If you have overweight or obesity and metabolic conditions like diabetes, you may experience reduced work effectiveness (presenteeism) and activity limitation. This is a measurable impact of your health conditions. Managing these conditions can help improve your work productivity and overall well-being.

Triple receptor agonists (GLP-1/GIP/Glucagon) such as retatrutide achieve superior weight loss (20-24%) compared to single or dual agonists by synergistically combining satiety, nutrient partitioning, and increased energy expenditure.

If you are struggling with current GLP-1 therapies or need more aggressive weight loss, triple-agonist medications like retatrutide are the next step. They work by hitting three metabolic targets at once, leading to much higher weight loss (up to 24%) than standard drugs. This is currently an injectable treatment, but oral alternatives are being developed.

Combining amylin analogs (e.g., cagrilintide) with GLP-1 agonists (e.g., semaglutide) achieves weight loss (20-22%) through distinct neuroendocrine circuits, offering a tolerability advantage over single agents.

If you are not getting enough weight loss or side effects from GLP-1s alone, adding an amylin analog (like cagrilintide) to your regimen might help. This combination works through a different mechanism in your brain and gut, leading to significant weight loss (around 20%) and potentially better tolerability.

In integrated primary care weight management, achieving clinically meaningful weight loss (≥5% initial body weight) is significantly associated with higher treatment visit frequency and the simultaneous prescription of two or more anti-obesity medications (AOMs).

To maximize your chances of losing at least 5% of your body weight, commit to attending your scheduled monthly appointments for the first six months and discuss with your doctor the potential benefit of using two anti-obesity medications simultaneously if one isn't working. Consistent engagement and combination therapy were key factors in successful weight loss trajectories in this study.